November is the month dedicated to men’s health. And prostate cancer is what we talk about the most. Especially for its numbers: it is in fact the second most commonly diagnosed cancer in men and the fifth cause of cancer death in males worldwide. Every year, in Italy, about 37 thousand new cases of prostate cancer are estimated, but thanks to the drugs developed in recent years, more than 90% are alive 5 years after diagnosis. Men with non-metastatic castration-resistant prostate cancer are generally active and have no symptoms, but are at high risk of developing metastatic disease; About one third of patients with castration-resistant non-metastatic prostate cancer develop metastases within two years. One of the most important challenges is therefore to avoid the onset of metastases, while maintaining the quality of life.
“November is the month dedicated to men’s health, and it is increasingly important to have effective weapons such as darolutamide to help patients with prostate cancer live better. Local symptoms related to the genitourinary system can adversely affect the quality of life of patients. Therefore, when choosing treatment in a patient with non-metastatic castration-resistant prostate cancer, it is important to evaluate drugs such as darolutamide that help to increase the life span, reducing the risk of complications related to the recurrence of the disease with an excellent profile of tolerability. Furthermore, better understanding the tolerability profile of a therapy helps prevent and manage unwanted adverse events such as fatigue, cognitive impairment and hypertension, ”says Daniele Santini, Professor of Medical Oncology at Campus Bio-Medico University of Rome. “The latest results presented confirm that treatment with darolutamide for an extended period allows patients to maintain an active social and working life.”
In the phase III ARAMIS study, darolutamide, an oral androgen receptor inhibitor, was shown to reduce the risk of death by 31% and improve metastasis-free survival, without compromising patients’ quality of life. Results that were confirmed by analyzes of the ARAMIS study presented to the Congress of the American Association of Urology and the Congress of the European Society of Medical Oncology that evaluated darolutamide in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The data from these analyzes provide further evidence that strengthens the known efficacy and tolerability profile of darolutamide in patients with castration-resistant non-metastatic prostate cancer, with significant progress in metastasis-free survival (MFS) and overall survival (OS). ), and a favorable safety profile over a prolonged treatment period comparable to androgen deprivation therapy (ADT) alone.